A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis

Nonalcoholic Steatohepatitis (NASH) With Fibrosis Clinical Trial

Official title:

A Phase 2, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of JKB-122 in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04255069
• Other study ID #: TWJ-NAF
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 30, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: February 2020
• Source: TaiwanJ Pharmaceuticals Co., Ltd
• Contact: Ying-Chu Shih, PhD
• Phone: +886-36587721
• Email: info[@]taiwanj.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A double-blind placebo controlled randomized Phase 2 study to determine if JKB-122 compared with placebo resolves NASH on liver biopsy and improves fibrosis

Description:

This is a Phase 2 study in which JKB-122 is given once daily for 52 weeks to subjects with Nonalcoholic steatohepatitis (NASH) with Fibrosis who have biopsy reading more than NAS 4 with a fibrosis reading more than 1 and no cirrhosis. Subjects will be at least 18 years of age, either male or female.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: December 31, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Is male or female, 18 years to 70 years of age.

2. If female of childbearing potential, must not be pregnant or breastfeeding and either postmenopausal (no menses for previous 12 months) or using an effective method of birth control (e.g., oral contraceptives, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy plus a barrier method).

3. Is diagnosed with non-alcoholic steatohepatitis (NASH) NAS >4.0

4. Compensated liver disease with the following hematologic, biochemical, and serological criteria on entry into protocol:

5. Subjects taking lipid lowering agents should keep their dose stable during the study.

6. Stable use of insulin sensitizing agents (PPARs, SGLT2 inhibitors, or GLP-1 agonists for 6 months prior to screening liver biopsy).

7. Is capable of understanding and signing the informed consent document. If subject is unable to sign the informed consent form, then the subject's legal representative or guardian may provide written consent per local regulations.

8. Agrees to comply with protocol requirements.

Exclusion Criteria:

1. Has human immunodeficiency virus (HIV) or is hepatitis B or C positive.

2. Has history of liver cirrhosis.

3. Has glycated hemoglobin (HbA1c ) greater than 9%.

4. Binge drinking as drinking 5 or more alcoholic drinks

5. Significant alcohol consumption

6. Is being treated with any prescription narcotic drug (including transdermal delivery systems).

7. Has a known or suspected central nervous system disorder that may predispose to seizures or lower the seizure threshold.

8. Has unstable and uncontrollable hypertension (>180/110 mmHg).

9. Has received other therapies for NAFLD in the last 4 weeks prior to the screening visit (Day -7).

10. Requires concomitant use of or treatment with opioids or other excluded drugs such as hepatotoxic medications.

11. Has received other investigational agents within 30 days prior to the screening visit (Day -7).

12. Has either autoimmune or genetic liver disease.

13. Alpha- fetoprotein greater than 20 mcg/L. Has impaired renal function (i.e. serum creatinine CLcr < 60 mL/min).

14. Subjects who gained or lost weight greater than 5 kg in the past 3 months.

15. Any form of chronic liver disease other than NASH

16. Suspected or confirmed cirrhosis. -

Related Conditions & MeSH terms

• Fatty Liver
• Fibrosis
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Intervention

Drug:
• Placebo
A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
• Dose 1 JKB-122
A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
• Dose 2 JKB-122
A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
TaiwanJ Pharmaceuticals Co., Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the effect of JKB-122 compared to placebo to achieve NASH resolution on liver histology in non-cirrhotic NASH patients with stage 2 or 3 fibrosis	Assessment will be based on the proportion of JKB-122 15 mg or 35 mg treated patients relative to placebo achieving NASH resolution with at least a 2 point reduction in NAS and no worsening of fibrosis	52 weeks
Primary	To evaluate the effect of JKB-122 compared to placebo to achieve a = 1 stage fibrosis improvement on liver histology in non-cirrhotic NASH patients with stage 2 or 3 fibrosis	Assessment will be based on the proportion of JKB-122 15 mg or 35 mg treated patients relative to placebo achieving at least a 1 stage improvement in fibrosis (NASH Clinical Research Network system) by liver biopsy with no worsening of NAS.	52 weeks
Secondary	Evaluate the changes of hepatic fat content	The changes of fatty liver content (%) will be measured by MRI-PDFF.	52 weeks
Secondary	Evaluate the changes of fibrosis score	The changes of fibrosis score (kPa) will be measured by FibroScan.	52 weeks